Chara Stavraka is an NIHR Academic Clinical fellow and Specialist Registrar in Medical Oncology at Guy's and St Thomas' NHS Foundation Trust.
She was awarded a competitive 3-year Imperial/CRUK clinical PhD fellowship to investigate the role of the RNA binding protein LARP1 as a post-trascriptional regulator of cisplatin resistance in ovarian cancer.
She graduated from the Medical School of the Aristotle University of Thessaloniki in 2009 and was awarded an MRes in Translational Medicine by Imperial College in 2010. She then worked as a Clinical Research Fellow in the early phase Clinical trials Unit of Imperial College gaining extensive experience in Phase I Oncology studies of molecularly targeted drugs. Having successfully completed her Core Medical Training she became a Member of the Royal College of Physicians (MRCP) in 2014.
Chara has presented her research in several highly esteemed international Oncology meetings and published in peer reviewed journals. Her efforts have been recognised with the prestigious Scholar in Training award by the American Association for Cancer Research in 2016.
She has been actively involved in undergraduate and postgraduate teaching both in the clinical and academic field and her contribution has been elected as an Associate Fellow of the Higher Education Academy.
et al., 2022, Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study, Cancers, Vol:14
et al., 2022, Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes, British Journal of Cancer, ISSN:0007-0920
et al., 2022, Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies, Clinical and Experimental Immunology, Vol:209, ISSN:0009-9104, Pages:4-21
et al., 2022, Clinical and Translational Significance of Basophils in Patients with Cancer, Cells, Vol:11
et al., 2022, Evaluation of an automated artificial intelligence (AI)/ natural language processing (NLP) engine to match patients (pts) with advanced solid cancers to biomarker-driven early phase (EP) clinical trials., LIPPINCOTT WILLIAMS & WILKINS, ISSN:0732-183X